Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Dual mTORC1/2 inhibition sensitizes testicular cancer models to cisplatin treatment.

Rosas-Plaza X, de Vries G, Meersma GJ, Suurmeijer AJH, Gietema JA, van Vugt MATM, de Jong S.

Mol Cancer Ther. 2019 Nov 19. pii: molcanther.0449.2019. doi: 10.1158/1535-7163.MCT-19-0449. [Epub ahead of print]

PMID:
31744897
2.

Platinum exposure and cause-specific mortality among patients with testicular cancer.

Groot HJ, van Leeuwen FE, Lubberts S, Horenblas S, de Wit R, Witjes JA, Groenewegen G, Poortmans PM, Hulshof MCCM, Meijer OWM, de Jong IJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJB, Jóźwiak K, van den Belt-Dusebout AW, Gietema JA, Schaapveld M.

Cancer. 2019 Nov 15. doi: 10.1002/cncr.32538. [Epub ahead of print]

PMID:
31730712
3.

The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective.

Sidorenkov G, Nagel J, Meijer C, Duker JJ, Groen HJM, Halmos GB, Oonk MHM, Oostergo RJ, van der Vegt B, Witjes MJH, Nijland M, Havenga K, Maduro JH, Gietema JA, de Bock GH.

J Transl Med. 2019 Nov 14;17(1):374. doi: 10.1186/s12967-019-2122-x.

4.

Heart failure after treatment for breast cancer.

Boekel NB, Duane FK, Jacobse JN, Hauptmann M, Schaapveld M, Sonke GS, Gietema JA, Hooning MJ, Seynaeve CM, Maas AHEM, Darby SC, Aleman BMP, Taylor CW, van Leeuwen FE.

Eur J Heart Fail. 2019 Nov 12. doi: 10.1002/ejhf.1620. [Epub ahead of print]

PMID:
31721395
5.

Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years.

Jacobse JN, Steggink LC, Sonke GS, Schaapveld M, Hummel YM, Steenbruggen TG, Lefrandt JD, Nuver J, Crijns APG, Aleman BMP, van der Meer P, Gietema JA, van Leeuwen FE.

Eur J Heart Fail. 2019 Nov 6. doi: 10.1002/ejhf.1610. [Epub ahead of print]

PMID:
31696625
6.

Laparoscopic Resection of Residual Retroperitoneal Tumor Mass in Advanced Nonseminomatous Testicular Germ Cell Tumors; a Feasible and Safe Oncological Procedure.

Öztürk Ç, Been LB, van Ginkel RJ, Gietema JA, Hoekstra HJ.

Sci Rep. 2019 Nov 1;9(1):15837. doi: 10.1038/s41598-019-52109-5.

7.

miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy.

Rosas Plaza X, van Agthoven T, Meijer C, van Vugt MATM, de Jong S, Gietema JA, Looijenga LHJ.

Cells. 2019 Oct 8;8(10). pii: E1221. doi: 10.3390/cells8101221.

8.

Cardiac Function After Radiation Therapy for Breast Cancer.

van den Bogaard VAB, van Luijk P, Hummel YM, van der Meer P, Schuit E, Boerman LM, Maass SWMC, Nauta JF, Steggink LC, Gietema JA, de Bock GH, Berendsen AJ, Smit WGJM, Sijtsema NM, Kierkels RGJ, Langendijk JA, Crijns APG, Maduro JH.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):392-400. doi: 10.1016/j.ijrobp.2019.02.003. Epub 2019 Feb 11.

PMID:
30763659
9.

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake.

Moek KL, Waaijer SJH, Kok IC, Suurs FV, Brouwers AH, Menke-van der Houven van Oordt CW, Wind TT, Gietema JA, Schröder CP, Mahesh SVK, Jorritsma-Smit A, Lub-de Hooge MN, Fehrmann RSN, de Groot DJA, de Vries EGE.

Clin Cancer Res. 2019 Jun 15;25(12):3517-3527. doi: 10.1158/1078-0432.CCR-18-2918. Epub 2019 Feb 11.

PMID:
30745297
10.

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.

Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.

PMID:
30686551
11.

Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA.

Boonstra PA, Ter Elst A, Tibbesma M, Gietema JA, Schuuring E, Reyners AKL.

Oncologist. 2019 Jun;24(6):e387-e390. doi: 10.1634/theoncologist.2018-0460. Epub 2019 Jan 22.

PMID:
30670599
12.

Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of β-hCG and cancer treatment.

Steggink LC, van Beek AP, Boer H, Meijer C, Lubberts S, Oosting SF, de Jong IJ, van Ginkel RJ, Lefrandt JD, Gietema JA, Nuver J.

Andrology. 2019 Jul;7(4):441-448. doi: 10.1111/andr.12581. Epub 2019 Jan 4.

PMID:
30609309
13.

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE.

Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26.

PMID:
30478423
14.

Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors.

Jacobse JN, Duane FK, Boekel NB, Schaapveld M, Hauptmann M, Hooning MJ, Seynaeve CM, Baaijens MHA, Gietema JA, Darby SC, van Leeuwen FE, Aleman BMP, Taylor CW.

Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):595-604. doi: 10.1016/j.ijrobp.2018.10.025. Epub 2018 Oct 29.

15.

Risk of diabetes after para-aortic radiation for testicular cancer.

Groot HJ, Gietema JA, Aleman BMP, Incrocci L, de Wit R, Witjes JA, Groenewegen G, de Brouwer P, Meijer OWM, Hulshof MCCM, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, van den Bergh ACM, Kerst JM, van den Belt-Dusebout AW, Lubberts S, Jóźwiak K, Horenblas S, van Leeuwen FE, Schaapveld M.

Br J Cancer. 2018 Oct;119(7):901-907. doi: 10.1038/s41416-018-0248-x. Epub 2018 Oct 9.

16.

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.

Ann Oncol. 2018 Aug 1;29(8):1658-1686. doi: 10.1093/annonc/mdy217.

PMID:
30113631
17.

Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer.

Boekel NB, Jacobse JN, Schaapveld M, Hooning MJ, Gietema JA, Duane FK, Taylor CW, Darby SC, Hauptmann M, Seynaeve CM, Baaijens MHA, Sonke GS, Rutgers EJT, Russell NS, Aleman BMP, van Leeuwen FE.

Br J Cancer. 2018 Aug;119(4):408-418. doi: 10.1038/s41416-018-0159-x. Epub 2018 Aug 1.

18.

Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.

Groot HJ, Lubberts S, de Wit R, Witjes JA, Kerst JM, de Jong IJ, Groenewegen G, van den Eertwegh AJM, Poortmans PM, Klümpen HJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, Incrocci L, van den Bergh ACM, Jóźwiak K, van den Belt-Dusebout AW, Horenblas S, Gietema JA, van Leeuwen FE, Schaapveld M.

J Clin Oncol. 2018 Aug 20;36(24):2504-2513. doi: 10.1200/JCO.2017.77.4174. Epub 2018 Jul 10.

PMID:
29989856
19.

Self-monitoring physical activity with a smartphone application in cancer patients: a randomized feasibility study (SMART-trial).

Ormel HL, van der Schoot GGF, Westerink NL, Sluiter WJ, Gietema JA, Walenkamp AME.

Support Care Cancer. 2018 Nov;26(11):3915-3923. doi: 10.1007/s00520-018-4263-5. Epub 2018 May 21.

20.

Avenues to molecular imaging of dying cells: Focus on cancer.

Rybczynska AA, Boersma HH, de Jong S, Gietema JA, Noordzij W, Dierckx RAJO, Elsinga PH, van Waarde A.

Med Res Rev. 2018 Sep;38(6):1713-1768. doi: 10.1002/med.21495. Epub 2018 Mar 12. Review.

21.

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.

de Vries Schultink AHM, Boekhout AH, Gietema JA, Burylo AM, Dorlo TPC, van Hasselt JGC, Schellens JHM, Huitema ADR.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):431-442. doi: 10.1007/s10928-018-9579-8. Epub 2018 Feb 10.

22.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML.

Invest New Drugs. 2018 Oct;36(5):828-835. doi: 10.1007/s10637-017-0551-z. Epub 2018 Jan 8.

23.

Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature.

Boonstra PA, Gietema JA, Suurmeijer AJH, Groves MR, de Assis Batista F, Schuuring E, Reyners AKL.

Oncotarget. 2017 Nov 26;8(65):109836-109847. doi: 10.18632/oncotarget.22663. eCollection 2017 Dec 12.

24.

Predictors of adherence to exercise interventions during and after cancer treatment: A systematic review.

Ormel HL, van der Schoot GGF, Sluiter WJ, Jalving M, Gietema JA, Walenkamp AME.

Psychooncology. 2018 Mar;27(3):713-724. doi: 10.1002/pon.4612. Epub 2018 Jan 26.

25.

Diastolic Dysfunction is Common in Survivors of Pediatric Differentiated Thyroid Carcinoma.

Klein Hesselink MS, Bocca G, Hummel YM, Brouwers AH, Burgerhof JGM, van Dam EWCM, Gietema JA, Havekes B, van den Heuvel-Eibrink MM, Corssmit EPM, Kremer LCM, Netea-Maier RT, van der Pal HJH, Peeters RP, Plukker JTM, Ronckers CM, van Santen HM, van der Meer P, Links TP, Tissing WJE.

Thyroid. 2017 Dec;27(12):1481-1489. doi: 10.1089/thy.2017.0383.

PMID:
29132262
26.

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.

Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, de Jong JR, Gietema JA, Schröder CP, Thomas M, Jacob W, Abiraj K, Adessi C, Meneses-Lorente G, James I, Weisser M, Brouwers AH, de Vries EGE.

Clin Cancer Res. 2017 Oct 15;23(20):6128-6137. doi: 10.1158/1078-0432.CCR-17-0311. Epub 2017 Jul 21.

27.

Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: A cross-sectional study.

Boerman LM, Maass SWMC, van der Meer P, Gietema JA, Maduro JH, Hummel YM, Berger MY, de Bock GH, Berendsen AJ.

Eur J Cancer. 2017 Aug;81:56-65. doi: 10.1016/j.ejca.2017.05.013. Epub 2017 Jun 8.

PMID:
28601706
28.

Therapeutic targeting and patient selection for cancers with homologous recombination defects.

Talens F, Jalving M, Gietema JA, Van Vugt MA.

Expert Opin Drug Discov. 2017 Jun;12(6):565-581. doi: 10.1080/17460441.2017.1322061. Epub 2017 May 2. Review.

PMID:
28425306
29.

NT-proBNP is increased in differentiated thyroid carcinoma patients and may predict cardiovascular risk.

Klein Hesselink EN, van der Horst-Schrivers ANA, van der Horst ICC, Bakker SJL, Muller Kobold AC, Brouwers AH, de Bock GH, Gietema JA, Dullaart RPF, Links TP, Lefrandt JD.

Clin Biochem. 2017 Aug;50(12):696-702. doi: 10.1016/j.clinbiochem.2017.02.020. Epub 2017 Feb 27.

PMID:
28242284
30.

Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures.

van den Bogaard VA, Ta BD, van der Schaaf A, Bouma AB, Middag AM, Bantema-Joppe EJ, van Dijk LV, van Dijk-Peters FB, Marteijn LA, de Bock GH, Burgerhof JG, Gietema JA, Langendijk JA, Maduro JH, Crijns AP.

J Clin Oncol. 2017 Apr 10;35(11):1171-1178. doi: 10.1200/JCO.2016.69.8480. Epub 2017 Jan 17. Erratum in: J Clin Oncol. 2017 Nov 10;35(32):3736.

31.

89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma.

van Es SC, Brouwers AH, Mahesh SVK, Leliveld-Kors AM, de Jong IJ, Lub-de Hooge MN, de Vries EGE, Gietema JA, Oosting SF.

J Nucl Med. 2017 Jun;58(6):905-910. doi: 10.2967/jnumed.116.183475. Epub 2017 Jan 12.

32.

Assessment of Volumetric versus Manual Measurement in Disseminated Testicular Cancer; No Difference in Assessment between Non-Radiologists and Genitourinary Radiologist.

Öztürk Ç, Velleman T, Bongaerts AH, Bergman LM, van Ginkel RJ, Gietema JA, Hoekstra HJ.

PLoS One. 2017 Jan 12;12(1):e0168977. doi: 10.1371/journal.pone.0168977. eCollection 2017.

33.

Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction.

Tromp J, Steggink LC, Van Veldhuisen DJ, Gietema JA, van der Meer P.

Clin Pharmacol Ther. 2017 Apr;101(4):481-490. doi: 10.1002/cpt.614. Epub 2017 Feb 14. Review. No abstract available.

PMID:
28073142
34.

Cancer treatment induced metabolic syndrome: Improving outcome with lifestyle.

Westerink NL, Nuver J, Lefrandt JD, Vrieling AH, Gietema JA, Walenkamp AM.

Crit Rev Oncol Hematol. 2016 Dec;108:128-136. doi: 10.1016/j.critrevonc.2016.10.011. Epub 2016 Nov 3. Review.

35.

Changes in taste and smell function, dietary intake, food preference, and body composition in testicular cancer patients treated with cisplatin-based chemotherapy.

IJpma I, Renken RJ, Gietema JA, Slart RHJA, Mensink MGJ, Lefrandt JD, Ter Horst GJ, Reyners AKL.

Clin Nutr. 2017 Dec;36(6):1642-1648. doi: 10.1016/j.clnu.2016.10.013. Epub 2016 Oct 27.

PMID:
27836309
36.

A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer.

Oosting SF, Chen TWW, Huang SH, Wang L, Waldron J, Gilbert R, Goldstein D, Halmos GB, Witjes MJH, Gietema JA, O'Sullivan B, Langendijk JA, Siu LL, Hansen AR.

Oral Oncol. 2016 Aug;59:43-49. doi: 10.1016/j.oraloncology.2016.05.016.

37.

[Docetaxel for metastatic prostate cancer: early is better].

Gietema JA, Oosting SF.

Ned Tijdschr Geneeskd. 2016;160:D215. Dutch.

PMID:
27405569
38.

The Sound of Silence: A Proxy for Platinum Toxicity.

Oldenburg J, Gietema JA.

J Clin Oncol. 2016 Aug 10;34(23):2687-9. doi: 10.1200/JCO.2016.68.2476. Epub 2016 Jul 5. No abstract available.

39.

Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.

Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH.

JAMA Oncol. 2016 Aug 1;2(8):1030-7. doi: 10.1001/jamaoncol.2016.1726.

PMID:
27348762
40.

Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers.

den Hollander MW, Westerink ND, Lubberts S, Bongaerts AH, Wolf RF, Altena R, Nuver J, Oosting SF, de Vries EG, Walenkamp AM, Meijer C, Gietema JA.

Oncologist. 2016 Aug;21(8):995-1001. doi: 10.1634/theoncologist.2015-0451. Epub 2016 Jun 21.

41.

Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy.

Lubberts S, Boer H, Altena R, Meijer C, van Roon AM, Zwart N, Oosting SF, Kamphuisen PW, Nuver J, Smit AJ, Mulder AB, Lefrandt JD, Gietema JA.

Eur J Cancer. 2016 Aug;63:180-8. doi: 10.1016/j.ejca.2016.05.022. Epub 2016 Jun 17.

PMID:
27322917
42.

Taste and smell function in testicular cancer survivors treated with cisplatin-based chemotherapy in relation to dietary intake, food preference, and body composition.

IJpma I, Renken RJ, Gietema JA, Slart RH, Mensink MG, Lefrandt JD, Ter Horst GJ, Reyners AK.

Appetite. 2016 Oct 1;105:392-9. doi: 10.1016/j.appet.2016.06.010. Epub 2016 Jun 10.

PMID:
27298084
43.

Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma.

van den Brom RR, van Es SC, Leliveld AM, Gietema JA, Hospers GA, de Jong IJ, de Vries EG, Oosting SF.

Cancer Treat Rev. 2016 May;46:63-72. doi: 10.1016/j.ctrv.2016.04.002. Epub 2016 Apr 16. Review.

44.

Long-term arterial complications of chemotherapy in patients with cancer.

Svilaas T, Lefrandt JD, Gietema JA, Kamphuisen PW.

Thromb Res. 2016 Apr;140 Suppl 1:S109-18. doi: 10.1016/S0049-3848(16)30109-8. Review.

PMID:
27067963
45.

Cardiotoxicity of breast cancer treatment: no easy solution for an important long-term problem.

van der Meer P, Gietema JA, Suter TM, van Veldhuisen DJ.

Eur Heart J. 2016 Jun 1;37(21):1681-3. doi: 10.1093/eurheartj/ehw133. Epub 2016 Apr 7. No abstract available.

PMID:
27055813
46.

Variation in the HFE gene is associated with the development of bleomycin-induced pulmonary toxicity in testicular cancer patients.

van der Schoot GGF, Westerink NL, Lubberts S, Nuver J, Zwart N, Walenkamp AME, Wempe JB, Meijer C, Gietema JA.

Eur J Cancer. 2016 May;59:134-141. doi: 10.1016/j.ejca.2016.02.013. Epub 2016 Mar 28.

PMID:
27033261
47.

Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors.

Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, Schinagl DA, Rietveld DH, Versteegh MI, Visser O, Rutgers EJ, Aleman BM, van Leeuwen FE.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1061-72. doi: 10.1016/j.ijrobp.2015.11.040. Epub 2015 Dec 14.

PMID:
27026313
48.

Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.

Boer H, Westerink NL, Altena R, Nuver J, Dijck-Brouwer DAJ, van Faassen M, Klont F, Kema IP, Lefrandt JD, Zwart N, Boezen HM, Smit AJ, Meijer C, Gietema JA.

Eur J Cancer. 2016 Feb;54:104-111. doi: 10.1016/j.ejca.2015.11.009. Epub 2016 Jan 2.

PMID:
26751392
49.

LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma.

Bults P, Bischoff R, Bakker H, Gietema JA, van de Merbel NC.

Anal Chem. 2016 Feb 2;88(3):1871-7. doi: 10.1021/acs.analchem.5b04276. Epub 2016 Jan 8.

PMID:
26713683
50.

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.

Lamberts LE, Menke-van der Houven van Oordt CW, ter Weele EJ, Bensch F, Smeenk MM, Voortman J, Hoekstra OS, Williams SP, Fine BM, Maslyar D, de Jong JR, Gietema JA, Schröder CP, Bongaerts AH, Lub-de Hooge MN, Verheul HM, Sanabria Bohorquez SM, Glaudemans AW, de Vries EG.

Clin Cancer Res. 2016 Apr 1;22(7):1642-52. doi: 10.1158/1078-0432.CCR-15-1272. Epub 2015 Nov 20.

Supplemental Content

Loading ...
Support Center